Report #2866566

Received Oct 17, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: Sep 1, 2025
Onset: Sep 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

second dose was on September 1, 2025,; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 12-FEB-2025). On 01-SEP-2025, the patient received the 2nd dose of Shingrix. On 01-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: second dose was on September 1, 2025,). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date:3 October 2025 The patient got the 1st dose of herpes zoster vaccine on 12-FEB-2025, and the second dose was on 01-SEP-2025 was it still effective or would need to get another vaccine. The reporter was ask even if there was a 7 month gap between doses it still works. The batch number was not provided and we and unable to contact the reporter.